ORKA
Oruka Therapeutics, Inc.Company Information
- Company Name
- Oruka Therapeutics, Inc.
- CIK
- CIK0000907654
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ORKA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ORKA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-02-14
- Last sale
- 2026-09-21
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 3,957,808
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 72,014,512
- Shares outstanding
- 62,872,318
- Ownership
- 114.54%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -12.01%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Related Party | - | 3 | 0 | 7 | 2 | 1 | 6 | 8 | - | - | - | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 268 | 50 | 47 | 91 | 65 | 84 | 62 | 411 | 33 | 36 | 37 | 38 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | 1 | 1 | 0 | 0 | ||||||
| Marketable Securities Current | 605 | 339 | 290 | 258 | 263 | 266 | 314 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 11 | 6 | 7 | 6 | 4 | 3 | 1 | 2 | - | - | - | - | ||||||
| Assets Current | 885 | 395 | 344 | 355 | 332 | 352 | 377 | 413 | 34 | 37 | 38 | 39 | ||||||
| Marketable Securities Noncurrent | 252 | 107 | 143 | 152 | 23 | 24 | 18 | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1,139 | 504 | 489 | 509 | 357 | 377 | 396 | 414 | 34 | 37 | 38 | 39 | ||||||
Liabilities Current | ||||||||||||||||||
| Employee Related Liabilities Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Other Accrued Liabilities Current | - | - | - | - | - | - | - | - | 1 | 1 | 0 | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | 5 | - | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Accounts Payable Trade Current | 8 | 4 | 4 | 2 | 5 | 4 | 3 | 2 | 1 | 1 | 0 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 14 | 9 | 11 | 9 | 4 | 6 | 3 | 2 | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | - | - | - | - | ||||||
| Liabilities Current | 23 | 17 | 15 | 21 | 12 | 12 | 13 | 18 | 1 | 2 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 25 | 18 | 17 | 22 | 14 | 12 | 14 | 19 | 1 | 2 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,375 | 705 | 658 | 643 | 470 | 466 | 463 | 397 | 226 | 226 | 226 | 226 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -0 | 1 | 0 | -0 | -0 | -0 | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -262 | -221 | -189 | -160 | -129 | -105 | -84 | -58 | -193 | -191 | -189 | -188 | ||||||
| Stockholders Equity | 1,115 | 487 | 472 | 487 | 344 | 365 | 382 | 342 | -29 | -7 | 37 | 38 | ||||||
| Liabilities And Stockholders Equity | 1,139 | 504 | 489 | 509 | 357 | 377 | 396 | 414 | 34 | 37 | 38 | 39 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | -20 | - | - | - | - | ||||||
| Series B Non Voting Convertible Preferred Stock Amount | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Series A Non Voting Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | - | - | - | - | ||||||
| Series B Non Voting Convertible Preferred Stock | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 545 | 545 | 545 | 545 | 545 | 545 | 545 | 545 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 61 | 50 | 49 | 48 | 37 | 37 | 37 | 35 | 15 | 15 | 15 | 14 | ||||||
| Shares Outstanding | 61 | 50 | 49 | 48 | 37 | 37 | 37 | 35 | 15 | 15 | 15 | 14 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOruka Therapeutics, Inc. (ORKA) — SEC Financial Statements & Analysis
Oruka Therapeutics, Inc. (ORKA) is a pharmaceutical preparations company, incorporated in DE. Oruka Therapeutics, Inc. trades on Nasdaq as: ORKA. Oruka Therapeutics, Inc. (ORKA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Oruka Therapeutics, Inc. carries a market cap of $5.98B, a P/E ratio of -45.03x, a P/B ratio of 5.37x, an enterprise value of $5.72B, and an EV/EBITDA multiple of -36.89x. On profitability, it posts a Return on Equity (ROE) of -18.23%, a Return on Assets (ROA) of -17.76%, and a Return on Invested Capital (ROIC) of -27.59%. Per share, it reports EPS of $-2.11, diluted EPS of $-2.11, free cash flow per share of $-1.61, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 32.92% year-over-year and EPS growth of -11.01% year-over-year. On the balance sheet, it maintains a current ratio of 38.51x, a quick ratio of 38.03x, working capital of $861.59M, a debt-to-equity ratio of 0.02x, a debt ratio of 0.02, an interest coverage ratio of -224.77x, free cash flow of $-101.19M (TTM), and net debt of $-268.47M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.98B
- P/E TTM
- -45.03x
- EPS TTM
- $-2.11
- P/B TTM
- 5.37x
- ROE TTM
- -18.23%
- ROA TTM
- -17.76%
- Debt To Equity
- 0.02x
- Free Cash Flow TTM
- $-101.19M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Oruka Therapeutics, Inc. in?
Oruka Therapeutics, Inc. (ORKA) operates in the Pharmaceutical Preparations industry.
What exchange does ORKA trade on?
Oruka Therapeutics, Inc. (ORKA) trades on the Nasdaq.
Where is Oruka Therapeutics, Inc. incorporated?
Oruka Therapeutics, Inc. is incorporated in DE.
When was Oruka Therapeutics, Inc. (ORKA)'s most recent SEC filing?
Oruka Therapeutics, Inc. (ORKA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is ORKA's market cap?
Oruka Therapeutics, Inc. (ORKA) has a market capitalization of $5.98B as of 2026-06-30.
What is ORKA's EPS (earnings per share)?
Oruka Therapeutics, Inc. (ORKA)'s trailing twelve month EPS is $-2.11 as of 2026-06-30.
What is ORKA's ROE (return on equity)?
Oruka Therapeutics, Inc. (ORKA)'s trailing twelve month Return on Equity (ROE) is -18.23% as of 2026-06-30.
What is ORKA's ROA (return on assets)?
Oruka Therapeutics, Inc. (ORKA)'s trailing twelve month Return on Assets (ROA) is -17.76% as of 2026-06-30.
What is ORKA's ROIC (return on invested capital)?
Oruka Therapeutics, Inc. (ORKA)'s trailing twelve month Return on Invested Capital (ROIC) is -27.59% as of 2026-06-30.
What is ORKA's EV/EBITDA?
Oruka Therapeutics, Inc. (ORKA)'s trailing twelve month EV/EBITDA is -36.89x as of 2026-06-30.